Phase II Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma

Trial Profile

Phase II Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Dianhydrogalactitol (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Del Mar Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 05 Apr 2017 Trial design presented at the American Association for Cancer Research (AACR) Annual Meeting 2017, according to a Delmar Pharmaceuticals, Inc. media release.
    • 13 Feb 2017 According to a DelMar Pharmaceuticals, media release, first patient has been dosed in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top